Solirna BioSciences

Work on single-stranded RNAi technology that Genesis had been conducting for its subsidiary Solirna Biosciences has also ceased, although it may restart if an existing investor provides additional financing.

Genesis said it once again needs additional financing to allow its subsidiary to demonstrate in vivo proof of principle for its ssRNAi, a milestone that will trigger additional funding by a key investor.

As reported by RNAi News earlier this month, the long-struggling Genesis recently received a commitment from Japanese biotech firm MediBic Group to invest up to NZ$1 million ($750,000) in the planned subsidiary, Solirna BioSciences.

According to Genesis, the primary investor in the subsidiary is Japan's MediBic Group, which is primarily a pharmacogenomics firm but has made investments in RNAi drug shop Intradigm.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.